Phase-changeable nanoparticles loaded with FeⅢ-tannic acid/paclitaxel for retinoblastoma treatment

In this study, phase-changeable nanoparticles consisting of poly(lactic-co-glycolic acid) (PLGA) shells with FeⅢ-tannic acid (FeⅢTA), paclitaxel (PTX), and perfluorinated pentane (PFP) were prepared, and their therapeutic effect on retinoblastoma (RB) was evaluated. The killing effect of the FeⅢTA/PLGA/PTX/PFP (FPTP) + laser (FPTP + laser) treatment on Y79 cells was stronger than that of the blank control, laser, and FPTP treatments. Moreover, this effect increased with increasing concentration. In vivo experiments showed that the nanoparticles clustered at the tumor sites in mice and that laser excitation produced heat. The tumor volume increased gradually over time in the blank control and laser groups but not in the PTX, PLGA/PTX/PFP + laser, and FPTP groups. The FPTP + laser group showed the best tumor-volume-reduction results. The results collectively suggest that FPTP nanoparticles have good therapeutic effects on RB and may potentially be applied as a new integrated approach for RB diagnosis and treatment. A new strategy for combined diagnostic imaging and treatment of retinoblastomas was demonstrated. Nanoparticles constructed from poly(lactic-co-glycolic acid) (PLGA) shells with FeⅢ-tannic acid (FeⅢTA), perfluorinated pentane (PFP), and the chemotherapy drug paclitaxel were shown to target retinoblastoma cells in vivo and in vitro. With laser irradiation, these FPTP nanoparticles effectively inhibited tumor cell proliferation and reduced tumor volumes. [Display omitted]